1. Vías de señalización
  2. GPCR/G Protein
  3. Protease Activated Receptor (PAR)

Protease Activated Receptor (PAR)

Thrombin receptors

Protease activated receptors (PARs) are a family of G-protein-coupled receptors (GPCRs) that are irreversibly activated by proteolytic cleavage of the N terminus, which unmasks a tethered peptide ligand that binds and activates the transmembrane receptor domain, eliciting a cellular cascade in response to inflammatory signals and other stimuli. There are four members of the PAR family: PAR1, PAR2, PAR3 and PAR4. PARs have important functions in the vasculature, inflammation, and cancer and are important drug targets.

PARs are expressed on nearly all cell types in the blood vessel wall (ECs, fibroblasts, myocytes) and blood (platelets, neutrophils, macrophages, leukemic white cells) with exception of red blood cells. Thrombin-activated PAR-1, PAR-3, and PAR-4 are also expressed in epithelium, neurons, astrocytes, and immune cells. PAR-2, which is activated by trypsin-like serine proteases, is found in human vascular, intestinal, neuronal, and airway cells. Its expression increases in injured tissues or after stimulation by inflammatory mediators.

Cat. No. Nombre del producto Efecto Pureza Chemical Structure
  • HY-143314
    Protease-Activated Receptor-1 antagonist 2
    Antagonist
    Protease-Activated Receptor-1 antagonist 2 is an orally active protease-activated receptor-1 (PAR-1) antagonist, with an IC50 value of 7 nM. Protease-Activated Receptor-1 antagonist 2 has favorable pharmacokinetic properties which is useful in the research of cardiovascular disease (CVD), such as atherosclerosis and restenosis.
    Protease-Activated Receptor-1 antagonist 2
  • HY-143313
    Protease-Activated Receptor-1 antagonist 1
    Antagonist
    Protease-Activated Receptor-1 antagonist 1 (Compound 13) is a protease-activated receptor-1 (PAR-1) antagonist with the IC50 of 3 nM by FLIPR technology. Protease-Activated Receptor-1 antagonist 1 can be used for the research of thrombotic cardiovascular, myocardial infarction, and peripheral arterial disease.
    Protease-Activated Receptor-1 antagonist 1
  • HY-P5357
    SFNGGP-NH2
    SFNGGP-NH2 is a biological active peptide. (PAR-3 is a high-affinity thrombin receptor. PAR-3 mRNA is expressed in the cutaneous mast cells of humans. Protease-Activated Receptors (PARs) have been studied for their roles in itch and their itch-associated response through histamine-dependent/independent pathways have been reported. PAR-3 has been shown not to induce itching alone but possibly in conjunction with PAR-4. Co-expression of PAR-3 and PAR-4 enhances thrombin action suggesting that PAR-3 alone does not mediate transmembrane signaling but instead functions as a cofactor to activate PAR-4.)
    SFNGGP-NH2
  • HY-P1314A
    2-Furoyl-LIGRLO-amide TFA
    Agonist
    2-Furoyl-LIGRLO-amide TFA is a potent and selective proteinase-activated receptor 2 (PAR2) agonist with a pD2 value of 7.0..
    2-Furoyl-LIGRLO-amide TFA
  • HY-P1310A
    VKGILS-NH2 TFA
    Agonist
    VKGILS-NH2 TFA is a reversed amino acid sequence control peptide for SLIGKV-NH2 (protease-activated receptor 2 (PAR2) agonist). VKGILS-NH2 TFA has no effect on DNA synthesis in cells.
    VKGILS-NH2 TFA
  • HY-404056
    (R)-AZ8838
    Antagonist
    (R)-AZ8838 is a competitive PAR2 antagonist with a pKi of  5.2 for human PAR2. (R)-AZ8838 exert anti-inflammatory effects in a rat model of PAR2 agonist-induced paw oedema.
    (R)-AZ8838
  • HY-169124
    Apoptosis inducer 28
    Activator
    Apoptosis Inducer 28 (Compound X1) is an apoptosis-inducing agent with anticancer activity in vitro. Apoptosis Inducer 28 can arrest the cell cycle at the G1 phase, promote cell death, and induce apoptosis by disrupting mitochondrial membrane potential. Apoptosis inducer 28 can also decrease the production of reactive oxygen species, downregulate the gene expression of BAX, Bcl-xL, and Bcl-2, while upregulating the gene expression of PAR-4.
    Apoptosis inducer 28
  • HY-120544
    BAY-386
    Antagonist
    BAY-386, a chemical probe, is a PAR-1 antagonist that inhibits the expression of pro-inflammatory factors MCP-1 and CXCL1 in HUVEC.
    BAY-386
  • HY-122049
    ENMD-1068 hydrobromide
    Antagonist
    ENMD-1068 hydrobromide is a potent PAR2 antagonist. ENMD-1068 hydrobromide attenuates joint inflammation in a dose-dependent manner. ENMD-1068 hydrobromide can be used in research of joint inflammation.
    ENMD-1068 hydrobromide
  • HY-P5875
    P4pal10
    Antagonist
    P4pal10 is an antagonist for protease-activated receptor 4 (PAR4). P4pal10 inhibits the platelet aggregation, inhibits tissue factor (TF)-induced thrombin generation, and exhibits anticoagulant and antithrombotic activities. P4pal10 reduces the oedema and the granulocyte infiltration induced by Carrageenan (HY-125474). P4pal10 ameliorates the injury in mice myocardial ischemia/reperfusion (I/R) models.
    P4pal10
  • HY-128345
    UDM-001651
    Antagonist
    UDM-001651 is a potent, selective, and orally bioavailable protease-activated receptor 4 (PAR4) antagonist (IC50=4 nM; Kd=1.4 nM). UDM-001651 shows antiplatelet potency (IC50=25 nM) in a γ-thrombin-induced platelet-rich plasma aggregation assay (γ-Thr PRP).
    UDM-001651
  • HY-P1262
    Parstatin(human)
    Agonist
    Parstatin(human), a cell-penetrating PAR-1 thrombin receptor agonist peptide, is a potent inhibitor of angiogenesis.
    Parstatin(human)
  • HY-128009
    ML161 analog 1
    Inhibitor 99.62%
    ML161 analog 1 (compound 38) is an analog of ML161 (HY-13965). ML161 analog 1 is a selective allosteric inhibitor of PAR1 with an IC50 of 1.68 μM.
    ML161 analog 1
  • HY-P1313
    PAR 4 (1-6) (human)
    Agonist
    PAR 4 (1-6) human, a hexapeptide, is a fragment of protease-activated receptor 4 (PAR4). PAR 4 (1-6) TFA acts as a PAR4-specific agonist.
    PAR 4 (1-6) (human)
  • HY-P2321A
    TRAP-6 amide TFA
    Agonist
    TRAP-6 amide TFA is a PAR-1 thrombin receptor agonist peptide.
    TRAP-6 amide TFA
  • HY-146333
    TRAP-6-IN-1
    Inhibitor
    TRAP-6-IN-1 (Compound 8) is a dual collagen and TRAP-6 inhibitor with IC50 values of 17.12 µM and 11.88 µM against collagen and TRAP-6, respectively. TRAP-6-IN-1 inhibits agonist-induced platelet aggregation in a non-competitive manner.
    TRAP-6-IN-1
  • HY-P5764
    TRAP-14 amide
    Agonist
    TRAP-14 amide, a proteinase activated receptor (PAR)-activating peptide, is a PAR agonist with an EC50 of 24 μM. TRAP-14 amide significantly induces platelet aggregation through ADP- and MMP-2-dependent pathways with Aspirin (HY-14654)-insensitivity. TRAP-14 amide also effectively increases glycoprotein (GP) Ib and GPIIb/IIIa surface expression and ADP release.
    TRAP-14 amide
  • HY-P1308A
    SLIGRL-NH2 TFA
    Agonist
    SLIGRL-NH2 TFA (Protease-Activated Receptor-2 Activating Peptide TFA) is an agonist of Protease-Activated Receptor-2 (PAR-2).
    SLIGRL-NH2 TFA
  • HY-18200B
    Atopaxar hydrobromide
    Antagonist
    Atopaxar (E5555) hydrobromide is a potent, orally active, selective and reversible thrombin receptor protease-activated receptor-1 (PAR-1) antagonist. Atopaxar hydrobromide, an antiplatelet agent, interferes with platelet signaling. Atopaxar hydrobromide can be used for the research of atherothrombotic disease.
    Atopaxar hydrobromide
  • HY-159896
    PAR4 antagonist 8
    Antagonist
    PAR4 antagonist 8 (Compound 20f) is an effective, orally active, and selective PAR4 antagonist with an IC50 value of 15.32 nM. PAR4 antagonist 8 exhibits favorable pharmacokinetic properties. PAR4 antagonist 8 not only effectively inhibits human platelet aggregation induced by PAR4 agonists (IC50 = 6.39 nM) but also inhibits mouse platelet aggregation. PAR4 antagonist 8 can be used in antithrombotic research.
    PAR4 antagonist 8
Cat. No. Nombre del producto / Synonyms Species Source

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.